The ENGAGE Study is a global study assessing the efficacy and safety of an investigational medication to determine whether it can slow the progression of symptoms in early Alzheimer’s disease.
There is an important medical and scientific need to research therapies that could delay memory loss and the progression of disability in Alzheimer’s disease because there are currently no approved treatments that slow the course of the condition.
What is the ENGAGE Study?
ENGAGE will compare whether monthly doses of aducanumab, given by IV, slows the progression of cognitive and functional impairment associated with Alzheimer’s Disease as compared to placebo treatment.
What is the Purpose of ENGAGE?
ENGAGE aims to evaluate the efficacy of aducanumab, a human antibody that targets beta-amyloid, in early Alzheimer’s Disease. Aducanumab or placebo will be given to patients with mild memory impairment via IV in this study.
Men and women ages 50-85 years old with a subjective or documented history of mild memory impairment or mild dementia. Please review theENGAGE flyerfor additional details about the trial.
If you are interested in learning more about the ENGAGE study, please call (401) 455-6403 or send an email to:firstname.lastname@example.org. Ask about the “ENGAGE study.”